DexCom (NASDAQ:DXCM) Cut to “Buy” at Wall Street Zen

Wall Street Zen cut shares of DexCom (NASDAQ:DXCM) from a strong-buy rating to a buy rating in a research report released on Sunday.

Several other equities research analysts also recently issued reports on the company. BTIG Research lowered their price target on DexCom from $109.00 to $85.00 and set a “buy” rating for the company in a report on Friday, October 31st. Robert W. Baird set a $82.00 target price on DexCom in a research note on Friday, October 31st. Royal Bank Of Canada dropped their target price on shares of DexCom from $100.00 to $85.00 and set an “outperform” rating on the stock in a report on Friday, October 31st. Stifel Nicolaus started coverage on shares of DexCom in a report on Tuesday, October 21st. They issued a “buy” rating and a $85.00 price target for the company. Finally, William Blair raised shares of DexCom to a “strong-buy” rating in a research report on Thursday, July 31st. Three research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and an average price target of $87.62.

DexCom Trading Up 2.9%

DXCM opened at $60.17 on Friday. The firm’s fifty day moving average is $66.49 and its two-hundred day moving average is $77.02. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The firm has a market cap of $23.47 billion, a PE ratio of 41.78, a price-to-earnings-growth ratio of 1.43 and a beta of 1.40. DexCom has a twelve month low of $54.11 and a twelve month high of $93.25.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.18 billion. During the same period last year, the firm posted $0.45 earnings per share. The business’s quarterly revenue was up 21.6% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. Equities research analysts anticipate that DexCom will post 2.03 EPS for the current year.

Insider Transactions at DexCom

In other DexCom news, Director Kyle Malady sold 667 shares of the business’s stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $80.86, for a total transaction of $53,933.62. Following the sale, the director directly owned 22,667 shares of the company’s stock, valued at $1,832,853.62. The trade was a 2.86% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Sadie Stern sold 1,466 shares of the stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $80.00, for a total transaction of $117,280.00. Following the transaction, the executive vice president owned 105,223 shares of the company’s stock, valued at approximately $8,417,840. This represents a 1.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 9,999 shares of company stock worth $619,391. 0.32% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Horizon Investments LLC grew its stake in shares of DexCom by 2.2% in the first quarter. Horizon Investments LLC now owns 5,608 shares of the medical device company’s stock valued at $383,000 after buying an additional 123 shares in the last quarter. Wedbush Securities Inc. lifted its stake in DexCom by 1.2% in the first quarter. Wedbush Securities Inc. now owns 13,168 shares of the medical device company’s stock valued at $899,000 after acquiring an additional 157 shares during the last quarter. GAMMA Investing LLC grew its position in shares of DexCom by 2.5% in the 3rd quarter. GAMMA Investing LLC now owns 7,043 shares of the medical device company’s stock valued at $474,000 after acquiring an additional 169 shares during the period. Inspire Investing LLC increased its stake in shares of DexCom by 6.1% during the 3rd quarter. Inspire Investing LLC now owns 3,139 shares of the medical device company’s stock worth $211,000 after purchasing an additional 180 shares during the last quarter. Finally, Argonautica Private Wealth Management Inc. raised its holdings in shares of DexCom by 3.2% in the 1st quarter. Argonautica Private Wealth Management Inc. now owns 5,958 shares of the medical device company’s stock valued at $407,000 after purchasing an additional 182 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.